Ladero J M, Arroyo R, De Andrés C, Jiménez-Jiménez F J, Molina J A, Varela de Seijas E, Giménez-Roldán S, Benítez J
Gastroenterology Service, Hospital Universitario San Carlos, University Complutense, Department of Medicine, Madrid, Spain.
Acta Neurol Scand. 1994 Feb;89(2):102-4. doi: 10.1111/j.1600-0404.1994.tb01643.x.
To elucidate whether any relationship exists between genetic polymorphic acetylation and the risk for multiple sclerosis (MS), we determined this polymorphism, using sulphamethazine, in 71 patients with definite MS and in 268 age-matched controls. Thirty-seven patients (52.1%) and 151 controls (56.3%) were classified as slow acetylators (not significant difference). No relation was found between acetylator polymorphism and age at onset of disease in MS patient's group. Our results do not support the existence of any relationship between acetylator polymorphism and the risk for MS.
为了阐明基因多态性乙酰化与多发性硬化症（MS）风险之间是否存在任何关联，我们使用磺胺二甲嘧啶对71例确诊为MS的患者和268例年龄匹配的对照者进行了该多态性的测定。37例患者（52.1%）和151例对照者（56.3%）被归类为慢乙酰化者（无显著差异）。在MS患者组中，未发现乙酰化者多态性与疾病发病年龄之间存在关联。我们的结果不支持乙酰化者多态性与MS风险之间存在任何关联。
